Citius Pharmaceuticals Announces Expansion of Institutional Orders for LYMPHIR®

What Happened

• On August 5, 2026, Citius Pharmaceuticals, Inc. filed a Form 8-K reporting that its wholly owned subsidiary, Citius Oncology, Inc., issued a press release announcing an update on an expanding base of institutional accounts ordering LYMPHIR®. The press release was furnished as Exhibit 99.1 to the filing.

Key Details

• Filing date: August 5, 2026 (Form 8-K, Item 8.01 - Other Events).
• Issuer of the announcement: Citius Oncology, Inc., a wholly owned subsidiary of Citius Pharmaceuticals.
• Subject: Expansion of institutional accounts ordering the company’s product LYMPHIR®.
• Press release is attached to the 8-K as Exhibit 99.1.

Why It Matters

• The announcement is a commercial update indicating growing institutional adoption of LYMPHIR®, which could be relevant to the company’s future sales, revenue, and quarterly results.
• The 8-K did not include financial results or quantitative sales figures; investors should look for follow-up disclosures (sales metrics, revenue impact, or quarterly filings) to evaluate the financial effect.